期刊文献+

舒利迭治疗特发性肺纤维化的效果及机制初步探讨 被引量:1

下载PDF
导出
摘要 目的探讨舒利迭(沙美特罗/丙酸氟替卡松)吸入剂治疗特发性肺纤维化(IPF)的效果,并观察治疗前后血清金属基质蛋白酶10(MMP-10)和转化生长因子-β(TGF-β)的表达变化。方法前瞻性入组医院收治的IPF患者100例,随机分为观察组(52例)和对照组(48例)。观察组给予舒利迭吸入剂(50/250μg)吸入治疗,2次/d;对照组口服强地松0.125 mg/kg。两组疗程均为3个月。观察记录两组的治疗前后的临床表现、血气、肺功能及不良反应,采用酶联免疫吸附法检测血清MMP-10和TGF-β水平。结果治疗3个月后,两组肺功能均得以改善,静息肺容量(VC)、一氧化碳弥散量(DLCO)/预计值较治疗前有明显好转,呼吸困难评分均减少(P<0.05),且观察组VC%和DLCO%显著高于对照组(P<0.05);两组MMP-10,TGF-β水平均下降,且观察组MMP-10和TGF-β水平均显著低于对照组(P<0.05)。结论用舒利迭吸入剂替代口服强的松治疗IPF,能取得较好的治疗效果,具有一定可行性;其机制可能与阻断TGF-β信号通路,抑制TGF-β上调MMP-10有关。
作者 白洁
出处 《西南国防医药》 CAS 2017年第11期1210-1212,共3页 Medical Journal of National Defending Forces in Southwest China
  • 相关文献

参考文献5

二级参考文献56

  • 1American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias,Am J Respir Crit Care Med,2002,165:277-304.
  • 2American Thoracic Society.Idiopathic pulmonary fibrosis:diagnosi and treatment.International consensus statement.American Thoracic Society (ATS),and the European Respiratory Society (ERS).Am J Rnspir Crit Care Med,2000,161:646-664.
  • 3Mapel DW,Samet JM,Coultas DB.Corticosteroids and the treatment of idiopathic pulmonary fibrosis.Past,present,and future.Chest,1996,110:1058-1067.
  • 4Gay SE,Kazerooni EA,Toews GB,et al.Idiopathic pulmonary fibrosis:predicting response to therapy and survival Am J Respir Crit Care Med,1998,157:1063-1072.
  • 5Flaherty KR,Toews GB,Lynch JP,et al.Steroids in idiopathic pulmonary fibrosis:a prospective assessment of adverse reactions,response to therapy,and survival Am J Med,2001,110:278-282.
  • 6Collard HR,Ryu JH,Douglas WW,et al.Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis,Chest,2004,125:2169-2174.
  • 7Rudd RM,Prescott RJ,Chalmers JC,et al.British Thoracic Society Study on cryptogenic fibrosing alveolitis:response to treatment and survival Thorax,2007,62:62-66.
  • 8Pereira CA, Malheiros T, Coletta EM, et al. Survival in idiopathic pulmonary fibrosis-cytixic agents compared to corticosteroids. Respir Med, 2006, 100 : 340-347.
  • 9Vogelmeier C. IPF or NSIP? That is the question. Eur Respir J,2003, 22: 191-192.
  • 10Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc, 2006, 3: 330-338.

共引文献420

同被引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部